JPWO2020210418A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210418A5 JPWO2020210418A5 JP2021559978A JP2021559978A JPWO2020210418A5 JP WO2020210418 A5 JPWO2020210418 A5 JP WO2020210418A5 JP 2021559978 A JP2021559978 A JP 2021559978A JP 2021559978 A JP2021559978 A JP 2021559978A JP WO2020210418 A5 JPWO2020210418 A5 JP WO2020210418A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- day
- cycle
- cycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 16
- 229960004641 rituximab Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229940125904 compound 1 Drugs 0.000 claims 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 5
- 201000003444 follicular lymphoma Diseases 0.000 claims 5
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833432P | 2019-04-12 | 2019-04-12 | |
| US62/833,432 | 2019-04-12 | ||
| PCT/US2020/027358 WO2020210418A1 (en) | 2019-04-12 | 2020-04-09 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527398A JP2022527398A (ja) | 2022-06-01 |
| JPWO2020210418A5 true JPWO2020210418A5 (https=) | 2023-04-17 |
| JP2022527398A5 JP2022527398A5 (https=) | 2023-04-17 |
| JP7562557B2 JP7562557B2 (ja) | 2024-10-07 |
Family
ID=70465546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559978A Active JP7562557B2 (ja) | 2019-04-12 | 2020-04-09 | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11390617B2 (https=) |
| EP (1) | EP3952880B1 (https=) |
| JP (1) | JP7562557B2 (https=) |
| KR (1) | KR102944213B1 (https=) |
| CN (1) | CN114144182B (https=) |
| AR (1) | AR119715A1 (https=) |
| AU (1) | AU2020270917B2 (https=) |
| BR (1) | BR112021020372A2 (https=) |
| CA (1) | CA3132538A1 (https=) |
| CL (1) | CL2021002651A1 (https=) |
| DK (1) | DK3952880T3 (https=) |
| ES (1) | ES3061998T3 (https=) |
| FI (1) | FI3952880T3 (https=) |
| HR (1) | HRP20251668T1 (https=) |
| IL (1) | IL287145A (https=) |
| LT (1) | LT3952880T (https=) |
| MA (1) | MA55608A (https=) |
| MX (1) | MX2021012507A (https=) |
| PT (1) | PT3952880T (https=) |
| RS (1) | RS67593B1 (https=) |
| SG (1) | SG11202111232RA (https=) |
| SI (1) | SI3952880T1 (https=) |
| SM (1) | SMT202600013T1 (https=) |
| TW (1) | TWI853014B (https=) |
| WO (1) | WO2020210418A1 (https=) |
| ZA (1) | ZA202107668B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| AU2020369497B2 (en) | 2019-10-21 | 2026-02-05 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| US11666579B2 (en) * | 2019-10-21 | 2023-06-06 | Celgene Corporation | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| CA3154890A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion |
| JP7676375B2 (ja) | 2019-10-21 | 2025-05-14 | セルジーン コーポレーション | （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンおよびその塩を含む固形体、並びにそれを含む組成物およびそれを使用する方法 |
| WO2021080955A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| CA3154908A1 (en) | 2019-10-21 | 2021-04-29 | Sreenivas S. Bhat | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam |
| AU2022252220A1 (en) * | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma |
| JP2024515108A (ja) * | 2021-04-21 | 2024-04-04 | セルジーン コーポレーション | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用して非ホジキンリンパ腫を治療する方法 |
| EP4326266A1 (en) * | 2021-04-21 | 2024-02-28 | Celgene Corporation | Methods of treating b-cell lymphoma using combination therapy |
| WO2022271557A1 (en) | 2021-06-21 | 2022-12-29 | Celgene Corporation | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002253795B2 (en) | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
| PL2076260T3 (pl) * | 2006-09-15 | 2011-08-31 | Celgene Corp | Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| BR112015002285B1 (pt) * | 2012-08-09 | 2022-05-10 | Celgene Corporation | Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer |
| HK1214552A1 (zh) | 2012-11-05 | 2016-07-29 | 细胞基因公司 | 在腎損傷的受試者中用泊馬度胺治療癌症 |
| CN105246480A (zh) * | 2013-04-02 | 2016-01-13 | 细胞基因公司 | 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 |
| CN111205268B (zh) * | 2014-10-30 | 2021-01-26 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| CN118344338A (zh) * | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
-
2020
- 2020-04-08 AR ARP200101015A patent/AR119715A1/es unknown
- 2020-04-09 BR BR112021020372A patent/BR112021020372A2/pt not_active Application Discontinuation
- 2020-04-09 SM SM20260013T patent/SMT202600013T1/it unknown
- 2020-04-09 JP JP2021559978A patent/JP7562557B2/ja active Active
- 2020-04-09 US US16/844,407 patent/US11390617B2/en active Active
- 2020-04-09 CN CN202080043197.0A patent/CN114144182B/zh active Active
- 2020-04-09 WO PCT/US2020/027358 patent/WO2020210418A1/en not_active Ceased
- 2020-04-09 AU AU2020270917A patent/AU2020270917B2/en active Active
- 2020-04-09 SG SG11202111232RA patent/SG11202111232RA/en unknown
- 2020-04-09 RS RS20251313A patent/RS67593B1/sr unknown
- 2020-04-09 TW TW109112033A patent/TWI853014B/zh active
- 2020-04-09 FI FIEP20722180.5T patent/FI3952880T3/fi active
- 2020-04-09 KR KR1020217036544A patent/KR102944213B1/ko active Active
- 2020-04-09 SI SI202030706T patent/SI3952880T1/sl unknown
- 2020-04-09 CA CA3132538A patent/CA3132538A1/en active Pending
- 2020-04-09 LT LTEPPCT/US2020/027358T patent/LT3952880T/lt unknown
- 2020-04-09 ES ES20722180T patent/ES3061998T3/es active Active
- 2020-04-09 PT PT207221805T patent/PT3952880T/pt unknown
- 2020-04-09 MA MA055608A patent/MA55608A/fr unknown
- 2020-04-09 DK DK20722180.5T patent/DK3952880T3/da active
- 2020-04-09 MX MX2021012507A patent/MX2021012507A/es unknown
- 2020-04-09 EP EP20722180.5A patent/EP3952880B1/en active Active
- 2020-04-09 HR HRP20251668TT patent/HRP20251668T1/hr unknown
-
2021
- 2021-10-08 CL CL2021002651A patent/CL2021002651A1/es unknown
- 2021-10-10 IL IL287145A patent/IL287145A/en unknown
- 2021-10-11 ZA ZA2021/07668A patent/ZA202107668B/en unknown
-
2022
- 2022-06-24 US US17/848,976 patent/US12103923B2/en active Active
-
2024
- 2024-08-09 US US18/799,483 patent/US20240400548A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021155426A5 (https=) | ||
| FI3952880T3 (fi) | 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dioni käytettäväksi non-hodgkinin lymfooman hoidossa | |
| JP2022121594A5 (https=) | ||
| JP2023002544A5 (https=) | ||
| JP2019517587A5 (https=) | ||
| JP2019516684A5 (https=) | ||
| JP2019536805A5 (https=) | ||
| JPWO2020210418A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| CN101678035A (zh) | 用于治疗糖尿病的选择性雄激素受体调节剂 | |
| JP2015212268A5 (https=) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2020517696A5 (https=) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| JP2020524670A5 (https=) | ||
| TW201822769A (zh) | 用於治療非小細胞肺癌之egfr t790m 抑制劑及cdk抑制劑之組合 | |
| JP2017516802A5 (https=) | ||
| JP2018090566A5 (https=) | ||
| IL292265B1 (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) | |
| JP2021169534A5 (https=) | ||
| JP2019524888A5 (https=) | ||
| JP2021501800A5 (https=) | ||
| JP2023011549A5 (https=) | ||
| JP2021512086A5 (https=) | ||
| JP2021521170A5 (https=) |